Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inhibitor of lipoprotein(a), or Lp(a), as a preclinical candidate (PCC) for the management of cardiovascular risks.